January 2024 in “Wiadomości Lekarskie” Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.
November 2025 in “Journal of Investigative Dermatology”
December 2025 in “npj Breast Cancer” Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
1 citations
,
January 2022 in “European Journal of Pharmacology” Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
1 citations
,
April 2025 in “American Journal of Medical Genetics Part C Seminars in Medical Genetics” Eflornithine improved symptoms in Bachmann–Bupp Syndrome patients.
January 2024 in “International journal of advanced biochemistry research” Fluralaner effectively cured dogs with severe skin issues caused by mites.
February 2024 in “Frontiers in Cell and Developmental Biology” Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.
35 citations
,
July 2022 in “Frontiers in Integrative Neuroscience” Formononetin may help protect the brain and treat neurological diseases.
1 citations
,
April 2024 in “Pathogens” A pet ferret had a serious infection from Mycobacterium xenopi, which can spread to humans.
1 citations
,
August 2022 in “International journal of women’s dermatology” Botox injections may be a safe and effective way to treat severe, itchy skin disease when other treatments fail.
January 2023 in “Revista Brasileira de Parasitologia Veterinária/Brazilian Journal of Veterinary Parasitology” A single dose of fluralaner effectively treats mite infestations in cats without side effects.
September 2021 in “Zenodo (CERN European Organization for Nuclear Research)”
3 citations
,
July 2020 in “Frontiers in Cell and Developmental Biology” Vitexin Compound 1 may help reduce skin aging caused by UVA light.
36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
31 citations
,
March 2014 in “Journal of the European Academy of Dermatology and Venereology” BRAF inhibitors for melanoma often cause skin side effects, but they can be managed with proper care.
82 citations
,
March 2013 in “PLoS ONE” Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.
13 citations
,
May 2010 in “Dermatologic Clinics” Recurrent furunculosis can be managed with antibiotics, decolonization, and decontamination, with potential future use of vaccines and bacteriophage therapy.
6 citations
,
January 2023 in “Medical Mycology Journal” Fosravuconazole effectively treated a woman's scalp infection without side effects.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
1 citations
,
April 2023 in “Heliyon” Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
9 citations
,
October 2015 in “Cutaneous and ocular toxicology” Vemurafenib can cause scalp issues but can be managed without changing the dose.
13 citations
,
November 2017 in “BMC Veterinary Research” Fusidic acid can be an effective topical treatment for superficial bacterial infections in dogs.
December 2010 in “Reactions Weekly” September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
January 2022 in “SSRN Electronic Journal” Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.
Dexmedetomidine-loaded microneedles effectively reduce pain without sedation.
1 citations
,
November 2018 in “Therapeutic Delivery” New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.